9th Annual European Antibody Congress, November 11–13, 2013, Geneva, Switzerland

References

• Reichert JM. Antibodies to watch in 2014. MAbs 2013; 6:5 - 14; PMID: 24284914
   PubMed Web of Science ®Google Scholar
• Ravn P, Madhurantakam C, Kunze S, Matthews E, Priest C, O(Brien S, Collinson A, Papworth M, Fritsch-Fredin M, Jermutus L, et al. Structural and pharmacological characterization of novel potent and selective monoclonal antibody antagonists of glucose-dependent insulinotropic polypeptide receptor. J Biol Chem 2013; 288:19760 - 72; http://dx.doi.org/10.1074/jbc.M112.426288; PMID: 23689510
   PubMed Web of Science ®Google Scholar
• Rust S, Guillard S, Sachsenmeier K, Hay C, Davidson M, Karlsson A, Karlsson R, Brand E, Lowne D, Elvin J, et al. Combining phenotypic and proteomic approaches to identify membrane targets in a ‘triple negative’ breast cancer cell type. Mol Cancer 2013; 12:11; http://dx.doi.org/10.1186/1476-4598-12-11; PMID: 23406016
   PubMed Web of Science ®Google Scholar
• DiGiandomenico A, Warrener P, Hamilton M, Guillard S, Ravn P, Minter R, Camara MM, Venkatraman V, Macgill RS, Lin J, et al. Identification of broadly protective human antibodies to Pseudomonas aeruginosa exopolysaccharide Psl by phenotypic screening. J Exp Med 2012; 209:1273 - 87; http://dx.doi.org/10.1084/jem.20120033; PMID: 22734046
   PubMed Web of Science ®Google Scholar
• Henderson SJ, Andersson C, Narwal R, Janson J, Goldschmidt TJ, Appelkvist P, Bogstedt A, Steffen AC, Haupts U, Tebbe J, et al. Sustained peripheral depletion of amyloid-β with a novel form of neprilysin does not affect central levels of amyloid-β. Brain 2013; http://dx.doi.org/10.1093/brain/awt308; PMID: 24259408
   PubMed Web of Science ®Google Scholar
• Jost C, Schilling J, Tamaskovic R, Schwill M, Honegger A, Plückthun A. Structural basis for eliciting a cytotoxic effect in HER2-overexpressing cancer cells via binding to the extracellular domain of HER2. Structure 2013; 21:1979 - 91; http://dx.doi.org/10.1016/j.str.2013.08.020; PMID: 24095059
   PubMed Web of Science ®Google Scholar
• Kummer L, Hsu CW, Dagliyan O, MacNevin C, Kaufholz M, Zimmermann B, Dokholyan NV, Hahn KM, Plückthun A. Knowledge-based design of a biosensor to quantify localized ERK activation in living cells. Chem Biol 2013; 20:847 - 56; http://dx.doi.org/10.1016/j.chembiol.2013.04.016; PMID: 23790495
   PubMed Web of Science ®Google Scholar
• Dreier B, Honegger A, Hess C, Nagy-Davidescu G, Mittl PR, Grütter MG, Belousova N, Mikheeva G, Krasnykh V, Plückthun A. Development of a generic adenovirus delivery system based on structure-guided design of bispecific trimeric DARPin adapters. Proc Natl Acad Sci U S A 2013; 110:E869 - 77; http://dx.doi.org/10.1073/pnas.1213653110; PMID: 23431166
   PubMed Web of Science ®Google Scholar
• Beck A, Wagner-Rousset E, Ayoub D, Van Dorsselaer A, Sanglier-Cianférani S. Characterization of therapeutic antibodies and related products. Anal Chem 2013; 85:715 - 36; http://dx.doi.org/10.1021/ac3032355; PMID: 23134362
   PubMed Web of Science ®Google Scholar
• Beck A, Sanglier-Cianférani S, Van Dorsselaer A. Biosimilar, biobetter, and next generation antibody characterization by mass spectrometry. Anal Chem 2012; 84:4637 - 46; http://dx.doi.org/10.1021/ac3002885; PMID: 22510259
   PubMed Web of Science ®Google Scholar
• Gahoual R, Burr A, Busnel JM, Kuhn L, Hammann P, Beck A, François YN, Leize-Wagner E. Rapid and multi-level characterization of trastuzumab using sheathless capillary electrophoresis-tandem mass spectrometry. MAbs 2013; 5:479 - 90; http://dx.doi.org/10.4161/mabs.23995; PMID: 23563524
   PubMed Web of Science ®Google Scholar
• Ayoub D, Jabs W, Resemann A, Evers W, Evans C, Main L, Baessmann C, Wagner-Rousset E, Suckau D, Beck A. Correct primary structure assessment and extensive glyco-profiling of cetuximab by a combination of intact, middle-up, middle-down and bottom-up ESI and MALDI mass spectrometry techniques. MAbs 2013; 5:699 - 710; http://dx.doi.org/10.4161/mabs.25423; PMID: 23924801
   PubMed Web of Science ®Google Scholar
• Panowksi S, Bhakta S, Raab H, Polakis P, Junutula JR. Site-specific antibody drug conjugates for cancer therapy. MAbs 2014; 6:34 - 45; http://dx.doi.org/10.4161/mabs.27022; PMID: 24423619
   PubMed Web of Science ®Google Scholar
• Behrens CR, Liu B. Methods for site-specific drug conjugation to antibodies. MAbs 2013; 6:46 - 53; PMID: 24135651
   PubMed Web of Science ®Google Scholar
• Wagner-Rousset E, Janin-Bussat MC, Colas O, Excoffier M, Haeuw JF, Rilatt I, Perez M, Corvaïa N, Beck A. Antibody Drug Conjugate model fast characterization by LC-MS following IdeS proteolytic digestion. MAbs 2013; 6:173 - 84; PMID: 24135617
   PubMed Web of Science ®Google Scholar
• LaFleur DW, Abramyan D, Kanakaraj P, Smith RG, Shah RR, Wang G, Yao XT, Kankanala S, Boyd E, Zaritskaya L, et al. Monoclonal antibody therapeutics with up to five specificities: functional enhancement through fusion of target-specific peptides. MAbs 2013; 5:208 - 18; http://dx.doi.org/10.4161/mabs.23043; PMID: 23575268
   PubMed Web of Science ®Google Scholar
• Beck A, Wurch T, Bailly C, Corvaïa N. Strategies and challenges for the next generation of therapeutic antibodies. Nat Rev Immunol 2010; 10:345 - 52; http://dx.doi.org/10.1038/nri2747; PMID: 20414207
   PubMed Web of Science ®Google Scholar
• Yang X, Xu W, Dukleska S, Benchaar S, Mengisen S, Antochshuk V, Cheung J, Mann L, Babadjanova Z, Rowand J, et al. Developability studies before initiation of process development: improving manufacturability of monoclonal antibodies. MAbs 2013; 5:787 - 94; http://dx.doi.org/10.4161/mabs.25269; PMID: 23883920
   PubMed Web of Science ®Google Scholar
• Lauer TM, Agrawal NJ, Chennamsetty N, Egodage K, Helk B, Trout BL. Developability index: a rapid in silico tool for the screening of antibody aggregation propensity. J Pharm Sci 2012; 101:102 - 15; http://dx.doi.org/10.1002/jps.22758; PMID: 21935950
   PubMed Web of Science ®Google Scholar
• Strop P, Liu SH, Dorywalska M, Delaria K, Dushin RG, Tran TT, Ho WH, Farias S, Casas MG, Abdiche Y, et al. Location matters: site of conjugation modulates stability and pharmacokinetics of antibody drug conjugates. Chem Biol 2013; 20:161 - 7; http://dx.doi.org/10.1016/j.chembiol.2013.01.010; PMID: 23438745
   PubMed Web of Science ®Google Scholar
• Farias SE, Strop P, Delaria K, Galindo Casas M, Dorywalska M, Shelton DL, Pons J, Rajpal A. Mass Spectrometric Characterization of Transglutaminase Based Site-Specific Antibody-Drug Conjugates. Bioconjug Chem 2014; http://dx.doi.org/10.1021/bc4003794; PMID: 24359082
   PubMed Web of Science ®Google Scholar
• Brezski RJ, Vafa O, Petrone D, Tam SH, Powers G, Ryan MH, Luongo JL, Oberholtzer A, Knight DM, Jordan RE. Tumor-associated and microbial proteases compromise host IgG effector functions by a single cleavage proximal to the hinge. Proc Natl Acad Sci U S A 2009; 106:17864 - 9; http://dx.doi.org/10.1073/pnas.0904174106; PMID: 19815504
   PubMed Web of Science ®Google Scholar
• Fan X, Brezski RJ, Fa M, Deng H, Oberholtzer A, Gonzalez A, Dubinsky WP, Strohl WR, Jordan RE, Zhang N, et al. A single proteolytic cleavage within the lower hinge of trastuzumab reduces immune effector function and in vivo efficacy. Breast Cancer Res 2012; 14:R116; http://dx.doi.org/10.1186/bcr3240; PMID: 22873525
   PubMed Web of Science ®Google Scholar
• Kinder M, Greenplate AR, Grugan KD, Soring KL, Heeringa KA, McCarthy SG, Bannish G, Perpetua M, Lynch F, Jordan RE, et al. Engineered protease-resistant antibodies with selectable cell-killing functions. J Biol Chem 2013; 288:30843 - 54; http://dx.doi.org/10.1074/jbc.M113.486142; PMID: 23986451
   PubMed Web of Science ®Google Scholar
• Ylera F, Harth S, Waldherr D, Frisch C, Knappik A. Off-rate screening for selection of high-affinity anti-drug antibodies. Anal Biochem 2013; 441:208 - 13; http://dx.doi.org/10.1016/j.ab.2013.07.025; PMID: 23906643
   PubMed Web of Science ®Google Scholar
• Frendéus B. Function-first antibody discovery: Embracing the unpredictable biology of antibodies. Oncoimmunology 2013; 2:e25047; http://dx.doi.org/10.4161/onci.25047; PMID: 24083074
   PubMedGoogle Scholar
• Loo D, Alderson RF, Chen FZ, Huang L, Zhang W, Gorlatov S, Burke S, Ciccarone V, Li H, Yang Y, et al. Development of an Fc-enhanced anti-B7-H3 monoclonal antibody with potent antitumor activity. Clin Cancer Res 2012; 18:3834 - 45; http://dx.doi.org/10.1158/1078-0432.CCR-12-0715; PMID: 22615450
   PubMed Web of Science ®Google Scholar
• Greaves P, Gribben JG. The role of B7 family molecules in hematologic malignancy. Blood 2013; 121:734 - 44; http://dx.doi.org/10.1182/blood-2012-10-385591; PMID: 23223433
   PubMed Web of Science ®Google Scholar
• Goetsch L, Haeuw JF, Beau-Larvor C, Gonzalez A, Zanna L, Malissard M, Lepecquet AM, Robert A, Bailly C, Broussas M, et al. A novel role for junctional adhesion molecule-A in tumor proliferation: modulation by an anti-JAM-A monoclonal antibody. Int J Cancer 2013; 132:1463 - 74; http://dx.doi.org/10.1002/ijc.27772; PMID: 22886345
   PubMed Web of Science ®Google Scholar
• Veitonmäki N, Hansson M, Zhan F, Sundberg A, Löfstedt T, Ljungars A, Li ZC, Martinsson-Niskanen T, Zeng M, Yang Y, et al. A human ICAM-1 antibody isolated by a function-first approach has potent macrophage-dependent antimyeloma activity in vivo. Cancer Cell 2013; 23:502 - 15; http://dx.doi.org/10.1016/j.ccr.2013.02.026; PMID: 23597564
   PubMed Web of Science ®Google Scholar
• Lee SH. Tanibirumab (TTAC-0001): a fully human monoclonal antibody targets vascular endothelial growth factor receptor 2 (VEGFR-2). Arch Pharm Res 2011; 34:1223 - 6; http://dx.doi.org/10.1007/s12272-011-0821-9; PMID: 21910042
   PubMed Web of Science ®Google Scholar
• Kuroda J, Nagoshi H, Shimura Y, Taniwaki M. Elotuzumab and daratumumab: emerging new monoclonal antibodies for multiple myeloma. Expert Rev Anticancer Ther 2013; 13:1081 - 8; http://dx.doi.org/10.1586/14737140.2013.829641; PMID: 24053207
   PubMed Web of Science ®Google Scholar
• McDonagh CF, Huhalov A, Harms BD, Adams S, Paragas V, Oyama S, Zhang B, Luus L, Overland R, Nguyen S, et al. Antitumor activity of a novel bispecific antibody that targets the ErbB2/ErbB3 oncogenic unit and inhibits heregulin-induced activation of ErbB3. Mol Cancer Ther 2012; 11:582 - 93; http://dx.doi.org/10.1158/1535-7163.MCT-11-0820; PMID: 22248472
   PubMed Web of Science ®Google Scholar
• Fitzgerald JB, Johnson BW, Baum J, Adams S, Iadevaia S, Tang J, Rimkunas V, Xu L, Kohli N, Rennard R, et al. MM-141, an IGF-1R and ErbB3 directed bispecific antibody, overcomes network adaptations that limit activity of IGF-1R inhibitors. Mol Cancer Ther 2013; •••; http://dx.doi.org/10.1158/1535-7163.MCT-13-0255; PMID: 24282274
   PubMed Web of Science ®Google Scholar
• Correia I, Sung J, Burton R, Jakob CG, Carragher B, Ghayur T, Radziejewski C. The structure of dual-variable-domain immunoglobulin molecules alone and bound to antigen. MAbs 2013; 5:364 - 72; http://dx.doi.org/10.4161/mabs.24258; PMID: 23572180
   PubMed Web of Science ®Google Scholar
• Jakob CG, Edalji R, Judge RA, Digiammarino E, Li Y, Gu J, Ghayur T. Structure reveals function of the dual variable domain immunoglobulin (DVD-Ig™) molecule. MAbs 2013; 5:358 - 63; http://dx.doi.org/10.4161/mabs.23977; PMID: 23549062
   PubMed Web of Science ®Google Scholar
• Gramer MJ, van den Bremer ET, van Kampen MD, Kundu A, Kopfmann P, Etter E, Stinehelfer D, Long J, Lannom T, Noordergraaf EH, et al. Production of stable bispecific IgG1 by controlled Fab-arm exchange: Scalability from bench to large-scale manufacturing by application of standard approaches. MAbs 2013; 5:961 - 72; http://dx.doi.org/10.4161/mabs.26233; PMID: 23995617
   PubMed Web of Science ®Google Scholar
• Klein C, Sustmann C, Thomas M, Stubenrauch K, Croasdale R, Schanzer J, Brinkmann U, Kettenberger H, Regula JT, Schaefer W. Progress in overcoming the chain association issue in bispecific heterodimeric IgG antibodies. MAbs 2012; 4:653 - 63; http://dx.doi.org/10.4161/mabs.21379; PMID: 22925968
   PubMed Web of Science ®Google Scholar
• Grosso JF, Jure-Kunkel MN. CTLA-4 blockade in tumor models: an overview of preclinical and translational research. Cancer Immun 2013; 13:5; PMID: 23390376
   PubMedGoogle Scholar
• Verbrugge I, Hagekyriakou J, Sharp LL, Galli M, West A, McLaughlin NM, Duret H, Yagita H, Johnstone RW, Smyth MJ, et al. Radiotherapy increases the permissiveness of established mammary tumors to rejection by immunomodulatory antibodies. Cancer Res 2012; 72:3163 - 74; http://dx.doi.org/10.1158/0008-5472.CAN-12-0210; PMID: 22570253
   PubMed Web of Science ®Google Scholar
• Verbrugge I, Gasparini A, Haynes NM, Hagekyriakou J, Galli M, Stewart TJ, Abrams TI, Yagita H, Verheij M, Johnstone RW, et al. The curative outcome of radio-immunotherapy in a mouse breast cancer model relies on mTOR signaling. Radiat Res 2014; In press
   PubMed Web of Science ®Google Scholar
• Chan AC, Carter PJ. Therapeutic antibodies for autoimmunity and inflammation. Nat Rev Immunol 2010; 10:301 - 16; http://dx.doi.org/10.1038/nri2761; PMID: 20414204
   PubMed Web of Science ®Google Scholar
• Fennell BJ, McDonnell B, Tam AS, Chang L, Steven J, Broadbent ID, Gao H, Kieras E, Alley J, Luxenberg D, et al. CDR-restricted engineering of native human scFvs creates highly stable and soluble bifunctional antibodies for subcutaneous delivery. MAbs 2013; 5:882 - 95; http://dx.doi.org/10.4161/mabs.26201; PMID: 23995618
   PubMed Web of Science ®Google Scholar
• Suntharalingam G, Perry MR, Ward S, Brett SJ, Castello-Cortes A, Brunner MD, Panoskaltsis N. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med 2006; 355:1018 - 28; http://dx.doi.org/10.1056/NEJMoa063842; PMID: 16908486
   PubMed Web of Science ®Google Scholar
• Janin-Bussat MC, Tonini L, Huillet C, Colas O, Klinguer-Hamour C, Corvaïa N, Beck A. Cetuximab Fab and Fc N-glycan fast characterization using IdeS digestion and liquid chromatography coupled to electrospray ionization mass spectrometry. Methods Mol Biol 2013; 988:93 - 113; http://dx.doi.org/10.1007/978-1-62703-327-5_7; PMID: 23475716
   PubMedGoogle Scholar
• Lynaugh H, Li H, Gong B. Rapid Fc glycosylation analysis of Fc fusions with IdeS and liquid chromatography mass spectrometry. MAbs 2013; 5:641 - 5; http://dx.doi.org/10.4161/mabs.25302; PMID: 23839239
   PubMed Web of Science ®Google Scholar
• Weise M, Bielsky MC, De Smet K, Ehmann F, Ekman N, Narayanan G, Heim HK, Heinonen E, Ho K, Thorpe R, et al. Biosimilars-why terminology matters. Nat Biotechnol 2011; 29:690 - 3; http://dx.doi.org/10.1038/nbt.1936; PMID: 21822237
   PubMed Web of Science ®Google Scholar
• Beck A. Biosimilar, biobetter and next generation therapeutic antibodies. mAbs 2011; 3:107- 10; PMID:21285536; 10.4161/ mabs.3.2.14785.
   Google Scholar
• Schneider CK, Kalinke U. Toward biosimilar monoclonal antibodies. Nat Biotechnol 2008; 26:985 - 90; http://dx.doi.org/10.1038/nbt0908-985; PMID: 18779806
   PubMed Web of Science ®Google Scholar
• Reichert JM, Beck A, Iyer H. European Medicines Agency workshop on biosimilar monoclonal antibodies: July 2, 2009, London, UK. MAbs 2009; 1:394 - 416; http://dx.doi.org/10.4161/mabs.1.5.9630; PMID: 20065643
   PubMedGoogle Scholar
• Beck A, Reichert JM. Therapeutic Fc-fusion proteins and peptides as successful alternatives to antibodies. MAbs 2011; 3:415 - 6; http://dx.doi.org/10.4161/mabs.3.5.17334; PMID: 21785279
   PubMed Web of Science ®Google Scholar
• Beck A, Reichert JM. Approval of the first biosimilar antibodies in Europe: a major landmark for the biopharmaceutical industry. MAbs 2013; 5:621 - 3; http://dx.doi.org/10.4161/mabs.25864; PMID: 23924791
   PubMed Web of Science ®Google Scholar
• Schiestl M, Stangler T, Torella C, Cepeljnik T, Toll H, Grau R. Acceptable changes in quality attributes of glycosylated biopharmaceuticals. Nat Biotechnol 2011; 29:310 - 2; http://dx.doi.org/10.1038/nbt.1839; PMID: 21478841
   PubMed Web of Science ®Google Scholar
• Beck A, Cochet O, Wurch T. GlycoFi’s technology to control the glycosylation of recombinant therapeutic proteins. Expert Opin Drug Discov 2010; 5:95 - 111; http://dx.doi.org/10.1517/17460440903413504; PMID: 22823974
   PubMed Web of Science ®Google Scholar
• Zhang N, Liu L, Dumitru CD, Cummings NR, Cukan M, Jiang Y, Li Y, Li F, Mitchell T, Mallem MR, et al. Glycoengineered Pichia produced anti-HER2 is comparable to trastuzumab in preclinical study. MAbs 2011; 3:289 - 98; http://dx.doi.org/10.4161/mabs.3.3.15532; PMID: 21487242
   PubMed Web of Science ®Google Scholar
• Beck A. Glycosylation Engineering of Biopharmaceuticals. Methods in Molecular Biology, Vol. 988. Beck, Alain (Ed.) Springer, 2013.
   Google Scholar